

HAMDARD INSTITUTE OF MEDICAL SCIENCES AND RESEARCH & ASSOCIATED HAH CENTENARY HOSPITAL

JAMIA HAMDARD (Deemed to be University)

GURU RAVIDAS MARG, HAMDARD NAGAR, NEW DELHI -110062

2022 MBBS Batch **2nd Phase Time Table**

Sr.	Day Data	9 AM 40 0 AM	O AM to 12 Noon	12 Noon to 1 PM	1 PM to 2 PM	2 PM to 3 PM	2 DM to 4 DM
No.	Day, Date	8 AM to 9 AM	9 AM to 12 Noon	12 Noon to 1 PM	1 PIVI to 2 PIVI	2 PIVI to 3 PIVI	3 PM to 4 PM
1	Saturday, 16 December, 2023	SU1.1 Describe Basic concepts of homeostasis, enumerate the metabolic changes in injury and their mediators. SU1.2 Describe the factors that affect the metabolic response to injury.	АЕТСОМ	FM 1.1 Basics and definitions, FM 1.2 History, FM1.3 Legal procedures FM1.4 Court procedures	LUNCH BREAK	Family Ado	ption Program
2	Sunday, 17 December, 2023			WEEKLYOFF			
3	Monday, 18 December, 2023	PA 1.1(L):Describe the role of a pathologist in diagnosis and management of disease		MI 1.1 : Introduction and History (L)		PA1.3:Practical- Introduction, Histotechnics, Identification of cells:,Microscope	
4	Tuesday, 19 December, 2023	PH 1.1: - (L) principles of pharmacology and Pharmacotherapeutics		PA 1.2 Enumerate common definitions and terms used in Pathology (Lecture)		FM 1.8 Describe the latest decisions related to medico- legal issued by Courts SGD	MI 1.1: Morphology and Physiology of bacteria (SGD)
5	Wednesday, 20 December, 202	PH 1.4: Absorption (L)		PA: 1.3 L: Describe the history and evolution of Pathology	LUNCH BREAK	MI 1.2: Microscopy a A/B); MI 1.1 Microsc	
6	Thursday, 21 December, 2023	MI 1.4 Sterilization & Disinfection (L)		PA: 2.1 (I)L: Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance		PH1.6 Describe principles of Pharmacovigilance & ADR reporting systems	
7	Friday, 22 December, 2023	OG 2.1 anatomy of genital tract		PH 1.4-SGD Factors affecting distribution		CM.11.4 (SGD) Descril ergonomics in health pr (SGD) Describe occupa professionals and their management	eservation CM.11.5 tional disorders of health
8	Saturday, 23 December, 2023			4th SATURDAYOFF	-	-	-
9	Sunday, 24 December, 2023			WEEKLYOFF			
10	Monday, 25 December, 2023			CHRISTMAS			

			PA: 2.1 L(II):			
			Demonstrate knowledge			
			of the causes,		FM2.3 Describe and	
					discuss issues related	MT O O C
			mechanisms, types and effects of cell injury and		to sudden natural	MI 8.9: Specimen
11	T 1 - 26 D 1 2022	DII 1 4 Distribution (II)	their clinical significance		deaths	collectionand
11	Tuesday, 26 December, 2023	PH 1.4- Distribution (L)			SGD	transport (SGD)
			PA:2.2 L: Describe the			
			etiology of cell injury.		DOAP PA.2.3 &	
			Distinguish between		Slide:, Fatty liver, Hya	
			reversible-irreversible		MI 1.5: Sterilisation a	nd disinfection &
			injury: mechanisms;		CSSD Visit (P), Grp A/	B; MI 1.4, 1.5
12	Wednesday, 27 December, 202	PH 1.4-Metabolism (L)	morphology of cell injury	LUNCH BREAK	Sterilization & Disinfe	ction (SGD)
			PA: 2.3 SGD: Intracellular			
			accumulation of fats,		PH1.7 Define, identify a	nd describe the
		MI: 1.1 Overview of Bacterial infections	proteins, carbohydrates,		management of adverse	
13	Thursday, 28 December, 2023	(L)	pigments		reactions (ADR)	
		(-/	p.g		CM 7.1 (Lecture) Define	Fnidemiology and
			PH 1.4 –SGD Factors		describe and enumerate	
14	Friday, 29 December, 2023	Practice of Medicine and Ethics in Medicine	affecting metabolism		and uses	1 1 , 1
			FM 1.6 offences, 1.7 dying			
			declaration and deposition,			
		SU1.3 Describe basic concepts of	1.9 Documentation in			
15	Saturday, 30 December, 2023	perioperative care	medical practice		Family Adop	otion Program
16	Sunday, 31 December, 2023		WEEKLYOFF			
					PA 2.4	: DOAP
		PA 2.4 L(I): Describe and discuss Cell	MI 1.1 Lab Diagnosis of		Slide: Caseous Ne	crosis, Coagulative
		death- types, mechanisms, necrosis,	Bacterial infections: I,		Neci	osis.
		apoptosis(basic as contrast with	Direct detection, staining			
17	Monday, 1 January, 2024	necrosis),autolysis PA:	(L)			
			PA 2.4 L(II): Describe and			
			discuss Cell death- types,		FM1.10 Select	
			mechanisms, necrosis,		appropriate cause of	MI 1.1:
			apoptosis(basic as		death in a particular	Conventional
			contrast with necrosis),		scenario by referring	methods of bacterial
18	Tuesday, 2 January, 2024	PH 1.4. Excretion (L)	autolysis.		ICD 10 code	identification (SGD)
	, , , , , , , , , , , , , , , , , , ,		PA:2.5 SGD: Describe and			,
			discuss pathologic		MI 1.1: Culture media	and methods (P).
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	discuss pathologic calcifications, gangrene		MI 1.1: Culture media	and methods (P),
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	calcifications, gangrene		MI 1.1: Culture media (SGD), Grp A/B	and methods (P),
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	calcifications, gangrene 2.6 SGD: Describe and			and methods (P),
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	calcifications, gangrene 2.6 SGD: Describe and discuss cellular	I UNCH DDE AV		and methods (P),
19	Wednesday, 3 January, 2024	PH 1.5 Mechanism Of Action	calcifications, gangrene 2.6 SGD: Describe and discuss cellular adaptations: atrophy,	LUNCH BREAK	(SGD), Grp A/B	and methods (P),
19	Wednesday, 3 January, 2024		calcifications, gangrene 2.6 SGD: Describe and discuss cellular adaptations: atrophy, hypertrophy,	LUNCH BREAK		and methods (P),
19	Wednesday, 3 January, 2024 Thursday, 4 January, 2024	PH 1.5 Mechanism Of Action MI 1.1 Lab Diagnosis of Bacterial infections II	calcifications, gangrene 2.6 SGD: Describe and discuss cellular adaptations: atrophy,	LUNCH BREAK	(SGD), Grp A/B PH1.8 Identify and	and methods (P),

21	Friday, 5 January, 2024 Saturday, 6 January, 2024	4.1-Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile response 4.2 Describe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia, HIV and travel SU2.1 Describe Pathophysiology of shock, types of shock & principles of resuscitation including fluid replacement and monitoring. SU2.2 Describe the clinical features of shock and its appropriate treatment.	AETCOM	PH 1.8: Drug Interactions (SGD) FM 3.1 Identification		CM 7.2 (SDL) Enumerate and discuss the modes of transmission and measures for prevention and control disease. CM 7.3 (SDL) Enumerate, describe and discuss the sources of epidemiological data PH1.9 Describe nomenclature of drugs i.e. generic, branded drugs
23	Sunday, 7 January, 2024		122100.11	WEEKLYOFF		generie, branded drugs
24	Monday, 8 January, 2024	PA: 2.7 L: Describe and discuss the mechanisms of cellular aging and apoptosis(N)		MI 1.1 Bacterial Genetics- (L)		DOAP PA 2.5 Slide: Monckeberg's Calcification,
25	Tuesday, 9 January, 2024	PH 1.5 –Receptors (L)		PA:3.1L: Describe the pathogenesis and pathology of amyloidosis		FM1.11 Write a correct cause of death certificate as per ICD 10 document SGD MI 1.1: Automated and molecular methods of bacterial identification (SGD)
26	Wednesday, 10 January, 2024	PH 1.13: Drug antagonism		PA:4.1 L(I): Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events	LUNCH BREAK	MI 1.2: Gram staining (P), Grp A/B
27				PA:4.1 L(II): Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular		PH1.10 Describe parts of a correct, complete and legible generic prescription. Identify errors in prescription and correct
27	Thursday, 11 January, 2024 Friday, 12 January, 2024	MI 1.6 Antimicrobials-1 (L) OG 3.1 Physiology of Menstruation, ovulation, fertilization and		PH 1.13 (SGD) Bioassay and biostandardization		PH1.12 CM 7.2(Lecture) Enumerate, describe and discuss the modes of transmission and measures for prevention and control disease
29	Saturday, 13 January, 2024	V. Martonjier embatton unu		O O O MARIO		measures for prevention and control disease
30	Sunday, 14 January, 2024	Implantation				
31	Monday, 15 January, 2024	PA:4.2 L: Enumerate and describe the mediators of acute inflammation		MI 1.6 Antimicrobials-2 (L)		PA 2.6 ; DOAP Slides - Metaplasia, dysplasia.

32	Tuesday, 16 January, 2024	PH 1.13: (L) Principles of Pharmacovigilance & ADR reporting systems		PA:4.3 L: Define and describe chronic inflammation including causes, types enumerate types, non-specific and granulomatous; and examples of each		FM 2.19 Investigation of anaesthetic, operative deaths	MI 1.6: Antimicrobial susceptibility testing (SGD)
33	Wednesday, 17 January, 2024	PH 1.14:management of adverse drug reactions (ADR)		PA: 5.1 L: Define and describe the process of repair and regeneration including wound healing and its types		MI 1.1: Morphology o	
				PA: 6.1 L: Demonstrate knowledge of the causes, pathogenesis, types and effects of edema and their clinical significance	LUNCH BREAK	PH1.12Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal	
34	Thursday, 18 January, 2024 Friday, 19 January, 2024	MI 1.1: General Virology (L) 4.3:Discuss and describe the common causes, pathophysiology and manifestations of fever in various regions in India including bacteria (enteric fever) parasitic (Filiariasis, ascariasis)		PH 1.13 (SGD) Bioassay and biostandardization		dysfunction CM 7.4 (Lecture)Define morbidity and mortality given set of data CM 7. define, describe and disc study designs	indicators based on 5 (Lecture)Enumerate,
36	Saturday, 20 January, 2024 Sunday, 21 January, 2024	SU2.3 Communicate and counsel patients and families about the treatment and prognosis of shock demonstrating empathy and care	AETCOM	FM 3.2 Identification WEEKLYOFF		Family Adop	otion Program
38	Monday, 22 January, 2024	PA: 6.2 SGD: Define & Describe Hyperemia , congestion Hemorrhage		MI 1.1 Overview of viral infections		of cell injumanifestations and cand mic	escribe various forms nries, their onsequences in gross roscopic imens
39	Tuesday, 23 January, 2024	PH 1.14-(Lecture) Adrenergic agonists		PA: 6.3 L: Define & describe Shock ,its pathogenesis , stages & clinical correlation	LUNCH BREAK	FM2.16 Describe and discuss examination of mutilated bodies or fragments, charred bones and bundle of bones SGD	MI 1.1: Normal microbial flora of human body (SGD)
40	Wednesday, 24 January, 2024	PH 1.15: (Lecture) Adrenergic antagonists		PA 6.4.1 SGD : Define and describe normal haemostasis		MI 1.1: Lab diagnosis Batch A/B	of viral infections (P),

41 42 43 44	Thursday, 25 January, 2024 Friday, 26 January, 2024 Saturday, 27 January, 2024 Sunday, 28 January, 2024	MI 1.1 General Parasitology (L)		PA: 6.4.2 L: Define and describe the etiopathogenesis and consequences of thrombosis REPUBLICDAY 4th SATURDAYOFF WEEKLYOFF		PH2.1 Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid	
45	Monday, 29 January, 2024	PA:6.5 L: Demonstrate knowledge of the causes ,types and effects of embolism and the clinical significance.	PA: 3.2 DOAP: Slide: Amyloidosis				
46	Tuesday, 30 January, 2024	PH 1.16 5-HT (L) Cholinergic agonist		PA;6.6 SGD: Define and describe Ischaemia/infarction its types, etiology, morphologic changes and clinical effects			II 1.1: Microbial
47	Wednesday, 31 January, 2024	PH 1.16 PG (L) Cholinergic Antagonists		PA: 7.1 L: Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread. Differentiate between Benign from Maignant neoplasm	LUNCH BREAK	MI 1.2: Lab diagnosis of p	parasitic infections
48	Thursday, 1 February, 2024	MI 1.1, General Mycology + Overview of Fungal infections (L)		PA:7.2L: Describe the molecular basis of cancer.		PH2.2 Prepare oral rehydration solution from ORS packet and explain its use	
49	Friday, 2 February, 2024	Discuss and describe the common causes, pathophysiology and manifestations of fever in various regions in India and viral causes (e.g Dengue,DHF, chikungunya)		PH 1.14-(SGD) Types, doses, side effects, indications and contraindications of adr drugs		CM 7.5(SGD) Enumerate, discuss epidemiologica	
50	Saturday, 3 February, 2024	SU3.1 Describe the Indications and appropriate use of blood and blood products and complications of blood transfusion.	AETCOM	FM 3.3,3.4 Mechanical Injuries		PH2.3 Demonstrate the app an intravenous simulated envi	drip in a
51	Sunday, 4 February, 2024			WEEKLYOFF		PA: 4.4 DOAP: Ident	ify and describe
52	Monday, 5 February, 2024	PA: 7.3 L: Enumerate carcinogens and describe the process of carcinogenesis		MI 1.3: Epidemiology of infectious diseases (L)		acute and chronic inflatement and microscopic Gross & Slides : Acu Chronic chol	mmation in gross specimens ite appendicitis,

	T			1					
				PA:7.4 L: Describe the		FM2.18 Crime Scene			
				effects of tumour on the		Investigation	MI 8.5, 8.6:		
				host including		Practical	Biomedical waste		
53	Tuesday, 6 February, 2024	PH 1.16: Management of glaucoma		paraneoplastic syndrome			(SDL)		
				PA:7.5 L: Describe					
				immunology &	I IIIIGII DDE AV				
				immune response to	LUNCH BREAK	MI 1.1, 1.2: Lab diagn	osis of fungal		
54	Wednesday, 7 February, 2024	PH 1.16: NSAID- L		cancer(N)		infections (P), Batch	A/B		
				PA:8.1 SDL: Describe the		PH2.4 Demonstrate			
				diagnostic role of		the correct method of			
				cytology and its		calculation of drug			
				application in clinical		dosage in			
				care.		patients including			
		MI 1.7: Immunological mechanisms in		Care		those used in special			
55	Thursday, 8 February, 2024	health(Innate and Acquired) (L)				situations			
				PH 1.16- (SGD) types,					
				doses, side effects,					
				indications and					
5.0	Friday, 9 February, 2024	OC 4 15 atus and Blacouts		contraindications		Samuel Control of the	ate, define, describe and		
56	Saturday, 10 February, 2024	OG 4.1Fetus and Placenta		of:Cholinergic 2nd SATURDAYOFF		discuss epidemioic	gical study designs		
58	Sunday, 11 February, 2024		2nd SATURDAY OFF WEEKLY OFF						
36	Sunday, 11 February, 2024	D. 2000 D. H. H. J. J.		WEEKLIOFF					
		PA: 8.2 SGD: Describe the basis of		1710 G			5.1		
		exfoliative cytology including the		MI 1.8: Components of		SLIDE : GRANU	LATION TISSUE		
59	Monday, 12 February, 2024	technique & stains used		immune system 1 (L)					
				PA:8.3 SDL Observe a		FM4.11 Describe and			
				diagnostic cytology and		discuss euthanasia			
				its staining and interpret		SGD	MI 1.8: Antigen		
60	Tuesday, 13 February, 2024	PH1.32: Gout (L)		the specimen			(SDL)		
				PA:9.1 SGD: Describe the					
				principles and					
		PH1.33: Drug reatment of Bronchial		mechanisms involved in					
61	Wednesday, 14 February, 2024	_		immunity.		MI 1.2: Acid fast stain	ing (P) Batch A/B		
	1			PA: 9.2 L: Describe the	LUNCH BREAK				
				mechanism of	LUNCH DREAK				
		MI 1.8: Components of immune		hypersensitivity					
62	Thursday, 15 February, 2024	system 2 (L)		reactions.					
	,,	4.4:Describe and discuss the pathophysiology							
		and manifestations of inflammatory causes of							
		fever							
		4.5 :Describe and discuss the pathophysiology							
		and manifestations of malignant causes of							
		fever including hematologic and lymph node							
		malignancies		PH 1.26- (SGD) 5-HT			merate and evaluate the		
63	Friday, 16 February, 2024			modulating Drugs		need of scr	eening tests		
	4771	SU3.3 Counsel patients and family/ friends	, rmgo) (TD (0.53 ()		T			
64	Saturday, 17 February, 2024	for blood transfusion and blood donation.	AETCOM	FM 3.5 Mechanical Injuries		Family Adop	otion Program		
65	Sunday, 18 February, 2024			WEEKLYOFF					

66	Monday, 19 February, 2024	PA:9.3 L Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection.	MI 1.8: Antibody (L)		PA6.7 DOAP: Identify and describe the gross and microscopic features of infarction in a pathologic specimen slide. Gross: Splenic Infarct Slide: Thrombosis.		
67	Tuesday, 20 February, 2024	PH 1.24: Diuretics- (L)	PA: 9.4 SGD Define and describe autoimmunity. Enumerate autoimmune disorders. (N)		FM4.25 Clinical research & Ethics Discuss human experimentation including clinical trials SGD MI 8.5, 8.6: Needle stick injury (SGD)		
68	Wednesday, 21 February, 2024	PH 1.26: RAS- (L)	PA: 9.5 LECTURE: Define and describe the pathogenesis of Systemic Lupus Erythematosus	LUNCH BREAK	MI 1.2: Stool microscopy 2 (P), Batch A/B		
69	Thursday, 22 February, 2024	MI 1.8: Antigen antibody reactions 1 (L)	PA: 9.6 SDL: DefINE and describe the pathogenesis and pathology of HIV and AIDS		PH3.1 Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient		
70	Friday, 23 February, 2024	OG 6.1 Diagnosis of pregnancy	PH 1.28 PVD-SGD		CM 7.7(SGD)Describe and demonstrate the steps in the Investigation of an epidemic of communicable disease		
71	Saturday, 24 February, 2024		4th SATURDAY OFF	1			
72	Sunday, 25 February, 2024		WEEKLYOFF		DA-71 DOAD. Define and desifer		
73	Monday, 26 February, 2024	PA: 9.7 SGD: Define and describe the pathogenesis of other common autoimmune diseases(N)	MI 1.8: Antigen antibody reactions 2(L)		PA:7.1 DOAP: Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread. Differentiate between benign from maignant neoplams: Gross & Slides: Lipoma, Hemangioma		
74	Tuesday, 27 February, 2024	PH 1.27: Drug treatment of HTN -(L)	PA:10.1 SDL: Define and describe the pathogenesis and pathology of malaria.		FM4.27 Describe and discuss Ethical Guidelines for Biomedical Research on Human Subjects & Animals SGD MI 1.10: Immunodeficiency disorders (SGD)		
75	Wednesday, 28 February, 2024	PH 1.28-Drug treatment of Angina- (L)	PA: 10.2 SGD (IL): Define and describe the pathogenesis and pathology of cysticercosis.	LUNCH BREAK	MI 1.8, 8.15: Antigen- antibody reaction 1 (P), Batch A/B		

76	Thursday, 29 February, 2024	MI 1.8 Complement (L)		PA:10.3 SGD (IL): Define and describe the pathogenesis and pathology of leprosy		PH3.2 Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient
77	Friday, 1 March, 2024	4.8:Discuss and describe the pathophysiology, aetiology and clinical manifestations of fever of unknown origin (FUO) including in anormal host, neutropenic host, nosocomial host, and a host with HIV disease		PH 1.25-(SGD) Drugs used in shock		CM 7.8(Lecture) Describe the principles of association, causation and biases in epidemiological studies
78 79	Saturday, 2 March, 2024 Sunday, 3 March, 2024	SU5.1 Discuss normal wound healing and factors affecting healing. SU5.2 Discuss history & presentation in a patient with wounds.	AETCOM	FM 3.6 Mechanical Injuries WEEKLYOFF		PH3.3 Perform and interpret a critical appraisal (audit) of a given prescription
80	Monday, 4 March, 2024	PA:10.4 Define and describe the pathogenesis and pathology of common bacterial, viral, protozoal and helminthic diseases.		MI 1.8: Cell mediated immune response (L)		PA:7.1 DOAP: Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread. Differentiate between benign from maignant neoplams Slides: SCC & Adenocarcinoma
81	Tuesday, 5 March, 2024	PH 1.31: Drug treatment of Arrhythmia-1 (L)		PA:11.1 L: Describe pathogenesis, features of common cytogenetic abnormality & mutations in childhood(N)		FM3.1 IDENTIFICATION Bone Examination DOAP MI 1.11: Transplant and cancer immunology (SGD)
82	Wednesday, 6 March, 2024	PH1.25: : Drug treatment of DYSLIPIDEMIA –(L)		PA:11.2 SGD: Describe pathogenesis and pathology of tumour and tumour like conditions in infancy and childhood(N)	LUNCH BREAK	MI 1.8, 8.15: Antigen antibody reactions 2 (P), Batch A/B
83	Thursday, 7 March, 2024	MI 1.8: Humoral immune response (L)		PA:11.3 L: Describe pathogenesis of common storage disorders in infancy and childhood(N)		PH3.4 Perform a critical evaluation of the drug promotional literature
84	Friday, 8 March, 2024	OG 7.1 Physiological changes of pregnancy		PH 1.25: (SGD) side effects, indications and contraindications of the drugs used in congestive heart failure		CM 7.8(SGD) Describe the principles of association, causation and biases in epidemiological studies
85 86	Saturday, 9 March, 2024 Sunday, 10 March, 2024			2nd SATURDAYOFF WEEKLYOFF		
	, 10 11aten, 2021			EEHETOIT		

87	Monday, 11 March, 2024	PA:12.1 SGD(IL) Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohal.		MI 1.10: Hypersensitivity reactions (L)		PA 10.1 PA 10.2 Infections: slides: Malaria cysticercosis	
88	Tuesday, 12 March, 2024	PH 1.35: Drug treatment of Anemia- (L)		PA:12.2 SGD (IL) Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation		FM 3.1 X-ray Shoulder Joint Elbow DOAP	MI 1.9: Immunoprophylaxis
89	Wednesday, 13 March, 2024	PH 1.35: Thrombolytics		PA: 12.3 SGD Describe the pathogenesis of obesity and its consequences		MI 1.2: Acid fast stai	ining 2 (P), Batch A/B
90	Thursday, 14 March, 2024	MI 1.10: Autoimmunity (L)		PA: 13.1 SGD: Describe hematopoiesis & extramedullary hematopoiesis.	LUNCH BREAK	PH3.4 To recognise	and report an adverse
91	Friday, 15 March, 2024	4.16:Enumerate the indications and describe the findings in tests of inflammation and specific rheumatologic tests, serologic testing for pathogens including HIV, bone marrow aspiration and biopsy 4.18:Enumerate the indications for use of imaging in the diagnosis of febrile syndromes		PH 1.25: Plasma Expanders- (SGD)		for a study CM 6.1(SG	ulate a research question D) Formulate a research for a study
92	Saturday, 16 March, 2024	SU5.3 Differentiate the various types of wounds, and plan management of wounds. SU5.4 Discuss medico legal aspects of wounds	AETCOM	FM 3.7,3.8,3.9 – Firearm Injuries		Family Ador	ption Program
93	Sunday, 17 March, 2024		112100111	WEEKLYOFF		raminy race	yuon 110gium
94	Monday, 18 March, 2024	IA 1	IA 1	IA 1		IA 1	IA 1
95	Tuesday, 19 March, 2024	IA 1	IA 1	IA 1		IA 1	IA 1
96	Wednesday, 20 March, 2024	IA 1	IA 1	IA 1	LUNCH BREAK	IA 1	IA 1
97	Thursday, 21 March, 2024	IA 1	IA 1	IA 1		IA 1	IA 1
98	Friday, 22 March, 2024	IA 1	IA 1	IA 1		IA 1	IA 1
99	Saturday, 23 March, 2024			4th SATURDAYOFF			
100	Sunday, 24 March, 2024			WEEKLYOFF			
101	Monday, 25 March, 2024			HOLI			
102	Tuesday, 26 March, 2024	PH 1.37: Ant-Platelet drgs (L)		PA:13.2 SGD: Describe the role of anticoagulants in hematology		FM 3.1 X-ray Pelvis and Lower Limb DOAP	MI 2.4: Infections causing anaemia (SGD)

103	Wednesday, 27 March, 2024	PH 1.36- Fibrinolytics- (L)		PA:13.3 SGD Define and classify Anemia	LUNCH BREAK	PA 10.3 & PA 10.4 Infections : slides:	
104	Thursday, 28 March, 2024	MI 1.1: BSI, Sepsis, septic shock, CRBSI (L)		PA 13.4 SGD Enumerate and describe the investigations of anemia			
105	Friday, 29 March, 2024			GOODFRIDAY			
106	Saturday, 30 March, 2024	SU4.1 Describe Pathophysiology of Burns. SU4.2 Describe Clinical features, Diagnose type and extent of burns and plan appropriate treatment.		FM 3.10, 3.11,3.12 Regional injuries	LUNCH BREAK	CM 7.9(SGD) Describe and demonstrate the application of computers in epidemiology	
107	Sunday, 31 March, 2024			WEEKLYOFF			
108	Monday, 1 April, 2024	PA 14.1 L Describe iron metabolism		MI 2.1, 2.2: Infections of CVS: Rheumatic fever & Infective Endocarditis including HACEK agents (L)		PA: 13.1 DOAP: Describe hematopoiesis & extramedullary hematopoiesis. Slides: Bone marrow slide	
109	Tuesday, 2 April, 2024	PH 1.36: Types insulin(L)		PA:14.2 L Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia	LUNCH BREAK	FM 1.9 Age Estimation DOAP MI 1.1: Plague (SDL)	
110	Wednesday, 3 April, 2024	PH 1.36- Drug management of DM-2 (L)		PA: 15.1 L: Describe the metabolism of Vitamin B12 and the etiology and pathogenesis of B12 deficiency PA: 15.2 L: Describe		MI 2.3, 8.15: Sepsis, CRBSI, RF, IE (P), Batch A/B; MI 8.1: Brucellosis, Borellia & Leptospirosis (SGD)	
				laboratory investigations			
111	Thursday, 4 April, 2024 Friday, 5 April, 2024	MI 3.3: Enteric fever (L)		of macrocytic anemia. JUMA-TUL-VIDA			
113	Saturday, 6 April, 2024	SU4.3 Discuss the medico legal aspects in burn injuries. SU4.4 Communicate and counsel patients (burns) and families on the outcome and rehabilitation demonstrating empathy and care.	AETCOM	FM 4.2 Medical ethics, 4.3 Medical councils, 4.4 Medical register, 4.5 , 4.24 Rights/privileges of medical practitioner	LUNCH BREAK	PH3.5 To prepare and explain a list of P-drugs for a given case/condition	
114	Sunday, 7 April, 2024			WEEKLYOFF			
115	Monday, 8 April, 2024	PA:15.4 SGD: Enumerate the differences and describe the distinguishing features of megaloblastic and non-megaloblastic macrocytic anemia(N)		MI 1.1: Rickettsial infections (L)	LUNCH BREAK	CERTIFIABLE SKILL PA: 13.5 DOAP: Perform, Identify and describe the peripheral blood picture in anemia Slides: Malaria	

116	Tuesday, 9 April, 2024						
117	Wednesday, 10 April, 2024			EID-UL-FITR*			
118	Thursday, 11 April, 2024	MI 2.7: HIV-1 (L)		PA:16.1 L: Define and classify haemolytic anaemia			Gram staining, Lab fever (P), Batch A/B
119	Friday, 12 April, 2024	OG 8.1, 8.2 Antenatal care		PH-1.36- (Types, doses of Iron formulations (SGD)	LUNCH BREAK	CM 6.2(SGD) Describe and discuss the principles and demonstrate the methods of collection and classification of statistical data	PH3.6 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs
120	Saturday, 13 April, 2024			2nd SATURDAYOFF			
121	Sunday, 14 April, 2024			WEEKLYOFF			
122	Monday, 15 April, 2024	PA:16.2 L: Describe the pathogenesis and clinical features and hematologic indices of haemolytic anaemia		MI 2.7: HIV-2 (L)		peripheral smear ir	ntify and describe the Microcytic anemia. ocytic anemia
123	Tuesday, 16 April, 2024	PH 1.37- Antithyrid Drugs (L)		PA: 16.3 L Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia	LUNCH BREAK	FM 1.9 Age Estimation DOAP	MI 1.1: Trypanosomiasis (SGD)
124	Wednesday, 17 April, 2024	TH Hot Thinnight Brugo (2)		RAMNAVAMI			(BGD)
125	Thursday, 18 April, 2024	MI 1.1: Dengue, Chikungunya and Zika (L)		PA:16.4 L: Describe the etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired haemolytic anaemia PA		MI 1.2: Gram staining 2 (P), Batch A/B	PH3.7 Prepare a list of essential medicines for a healthcare facility
126	Friday, 19 April, 2024	4.7:Discuss and describe the pathophysiology and manifestations of the sepsis		PH 1.37 HRT- SGD	LUNCH BREAK	CM 6.3(SGD) Describe the application of eleme including test of signi-	, discuss and demonstrate entary statistical methods ficance in various study signs
127 128	Saturday, 20 April, 2024 Sunday, 21 April, 2024	SU6.1 Define and describe the etiology and pathogenesis of surgical Infections	AETCOM	FM 4.6, 4.7 Laws in relation to medical practice FM 4.9 Medicolegal issues MAHAVIRJAYANTI		Family Adop	otion Program
120	5unday, 21 April, 2024			MAHAYINJAIANII	•	DA 15	3 DOAP
129	Monday, 22 April, 2024	16.5 L: Describe the peripheral blood picture in different haemolytic Anaemias		MI 2.5 & 1.1: Malaria, Babesiosis 1 (L)		Identify and describe picture of An	e the peripheral blood macrocytic emia ocytic anemia
130	Tuesday, 23 April, 2024	PH 1.37 Estrogen & Prog & their analogues (L)		PA 16.7 SDL Discribe the correct technique to perform a cross match		FM 3.6 Weapons Examination DOAP	MI 1.1: Viral hemorrhagic fever 2 (SGD)

131	Wednesday, 24 April, 2024	PH 1.39: OCP (L)	PA:17.1 L: Enumerate the etiology, pathogenesis and findings in aplastic anemia(N) PA:17.2 SGD: Enumerate the indications and describe the findings in bone marrow aspiration		Dengue (P), Ba Schistosom PH3.8 Communica	iagnosis of HIV and tch A/B, MI 1.1: iasis (SGD) te effectively with a proper use of	
132	Thursday, 25 April, 2024	MI 2.5 & 1.1: Malaria, Babesiosis 2 (L)	and biopsy(N)			medication	
133	Friday, 26 April, 2024	OG 8.7,8.8 Antenatal care cont.	PH 1.36: Calcium balance SGD)	(-	infections. Explain rearesponsible for emerger	nerging and reemerging sons or Identify factors and re-emergence of ous diseases.	
134	Saturday, 27 April, 2024		4th SATURDAY OF	F		-	
135	Sunday, 28 April, 2024	WEEKLYOFF					
136	Monday, 29 April, 2024	PA18.1 SDL Enumerate and describe the causes of leucocytosis leucopenia	MI 2.5: Leishmaniasis		Identify and describe picture of A	PA 18.2 DOAP Identify and describe the peripheral blood picture of AML,CML Slide: AML,CML	
137	Tuesday, 30 April, 2024	PH 1.40 Tt of infertility	PA: 18.2 L: Describe the etiology, genetics pathogenesis classification, features, hematologic features of acute leukemia	;,	FM 1.9 Medical Cause of Death SGD	MI 1.1: Systemic mycosis and candidiasis (SGD)	
138	Wednesday, 1 May, 2024	PH 1.36: Drug management of Osteoporosis-(L)	PA: 18.2 L: Describe the etiology, genetics, pathogenesis classification, features, hematologic features of chronic leukemia		MI 1.2: Acid fast stai	ning 3 (P), Batch A/B	
139	Thursday, 2 May, 2024	MI 2.5: Lymphatic filariasis (L)	PA:19.1 SGD: Enumerate the causes and describe the differentiating features of lymphadenopathy		routes in a	rugs through various simulated sing mannequins	

140	Friday, 3 May, 2024	4.6:Discuss and describe the pathophysiology and manifestations of Malaria 4.22:Describe and discuss the pharmacology, indications, adverse reactions, interactions of antimalarial drugs and basis of resistance 4.23:Prescribe drugs for malaria based on the species identified, prevalence of drug resistance and national program 4.24:Develop an appropriate empiric treatment plan based on the patient's clinical and immune status pending definitive diagnosis		PH-1.38 – (SGD) Drugs used in erectile dysfunction		demonstrate Common simple statistical r distribution, measures	amerate, discuss and a sampling techniques, methods, frequency of central tendency and ersion
141	Saturday, 4 May, 2024	SU6.2 Enumerate Prophylactic and therapeutic antibiotics. Plan appropriate management	AETCOM	FM 4.8 consumer protection act, 4.10 Communication, 4.11 euthanasia		pressure (and vaso-depressors wi using c	effects of drugs on blood vasopressor ith appropriate blockers) omputer learning
142	Sunday, 5 May, 2024	PA:19.2 SGD: Describe the pathogenesis		WEEKLYOFF		DA 16	6 DOAP
143	Monday, 6 May, 2024	and pathology of tuberculous lymphadenitis		MI 3.1: GI Infective syndromes (L)		Prepare a peripher identify anaemi Slide: Hemolytic	ral blood smear and hemolytic a from it. anemia,Sicklie cell emia
144	Tuesday, 7 May, 2024	PH-1.38: Corticosteroids (L)		PA:19.4 L Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's lymphoma		FM 1.9 Drunkenness Certificate DOAP	MI 3.5: Food poisoning and AAD (SGD)
145	Wednesday, 8 May, 2024	PH-1.41: (L) Anterior Pituitary hormones		PA:19.4 L Describe and discuss the pathogenesis, pathology and the differentiating features of non- Hodgkin's lymphoma	LUNCH BREAK		ia, Leishmaniasis & asis (P), Batch A/B
146	Thursday, 9 May, 2024	MI 3.1: Cholera and halophilic vibrio infections (L)		PA:19.6 SDL: Enumerate and differentiate the causes of splenomegaly.		empathy and	e with the patient with I ethics on all of drug use
147	Friday, 10 May, 2024	OG 14.1 Maternal pelvis and fetal skull		PCT		CM & BI 2.4 GM' components and new development. Describe	T:Describe Vaccine ver process of vaccine e the role of vaccines in 1 & eradication.
148	Saturday, 11 May, 2024			2nd SATURDAYOFF			
149	Sunday, 12 May, 2024			WEEKLYOFF			

150	Monday, 13 May, 2024	PA-20.1 L: Describe the features of plasma cell myeloma		MI 3.1: Intestinal amoebiasis & Balantidiasis (L)		Demonstrate the c	P: Describe and orrect technique to cross match.
151	Tuesday, 14 May, 2024	PH-1.41: (L) Drugs used in the treatment of infertility		PA:21.2 L: Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disorders including ITP		FM 1.9 Drunkenness Certificate DOAP	MI 3.1: Intestinal cestodes and trematodes (SGD)
152	Wednesday, 15 May, 2024	PH1.34: Prokinetic agents (L)		PA:21.3 L: Differentiate platelet from clotting disorders based on the clinical and hematologic features		diagnosis of shigell	: Gram staining, Lab losis, NTS, DEC (P) /B, SGD
				PA:21.4 L: Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated	LUNCH BREAK	regarding optim therapy, b) device	ate with the patient all use of a) drug es and c) storage of
153	Thursday, 16 May, 2024	MI 3.1: Intestinal nematodes 1 (L) 25.1:Describe and discuss the response and the influence of host, immune status, risk factors and comorbidities on zoonotic diseases (e.g.Leptospirosis, thypus) 25.2:Discuss and describe the common causes, pathophysiology and manifestations of these diseases		intravascular coagulation		medi	cines
154	Friday, 17 May, 2024	25.8:Enumerate the indications for use of newer techniques in the diagnosis of these infections		PH 1.34: uterine relaxants and stimulants – (SGD)		routine vaccination dur the role of commun	escribe the importance of ing pandemics. Describe nities in vaccination ammes.
155	Saturday, 18 May, 2024	SU7.1 Describe the Planning and conduct of Surgical audit	AETCOM	4.16 Bioethics		Family Ado	otion Program
156	Sunday, 19 May, 2024			WEEKLYOFF		, , , , ,	
157	Monday, 20 May, 2024	PA:21.5 L: Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of Vitamin K deficiency.		MI 3.1: Intestinal nematodes 2(L)		PA:19.3 DOAP: Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen	
158	Tuesday, 21 May, 2024	PH 1.34-Anti-Emetic agents- (L)		PA:22.1 L: Classify and describe blood group systems (ABO and RH)	LUNCH BREAK	FM 1.9 Injury Certificate DOAP	MI 3.6, 3.1: Helicobacter infections, campylobacter infections and Yersiniosis (SGD)

159	Wednesday, 22 May, 2024	PH 1.4: General principles of Chemotherapy – (L)		PA:22.2 SGD: Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing.		MI 3.1, 3.2, 8.15: Lab diagnosis of intestinal amoebiasis, giardiasis and coccidian parasites (P), Batches A/B & SGD
160	Thursday, 23 May, 2024			BUDDHAPURNIMA	<u> </u>	
161	Friday, 24 May, 2024	OG 13.1 (A) Physiology and mechanism		PH 1.43- (SGD) Chloramphenicol and tetracyclines	LUNCH BREAK	CM 14.1(Lecture) Define and classify hospital waste
162	Saturday, 25 May, 2024	61.1				
163	Sunday, 26 May, 2024	oflabour				
164	Monday, 27 May, 2024	PA:22.4 SGD: Enumerate blood components and describe their clinical uses.		MI 3.7: Agents of viral hepatitis 1 (L)		PA:19.5 DOAP Identify and describe the features of Hodgkin's lymphoma in gross and microscopic specimen
165	Tuesday, 28 May, 2024	PH 1.42- Penicillins – 1(L)		PA:22.5 L: Enumerate and describe infections transmitted by blood transfusion.		FM 1.9 Injury Certificate DOAP MI 3.1: Viral gastroenteritis (SDL)
166	Wednesday, 29 May, 2024	PH-1.42: Penicillins −2 (L)		PA:22.6 L: Describe transfusion reactions and enumerate the steps in the investigation of a transfusion reaction		MI 1.2, 3.2, 8.15: Stool microscopy, intestinal nematodes and cestodes (P), Batch A/B
167	Thursday, 30 May, 2024	MI 3.7: Agents of viral hepatitis 2		PA 22.7 SGDEnumerate the indications and describe the principles and and procedure of autologous transfusion	LUNCH BREAK	PH5.3 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
168	Friday, 31 May, 2024	25.1:Describe and discuss the response and the influence of host, immune status, risk factors and comorbidities on zoonotic diseases (e.g. Rabies) and non-febrile infectious disease (e.g. Tetanus) 25.2:Discuss and describe the common causes, pathophysiology and manifestations of these diseases 25.8:Enumerate the indications for use of newer techniques in the diagnosis of these infections		PH 1.43, 1.55-SGD		CM 14.2 (Lecture)Describe various methods of treatment of hospital waste. CM 14.2(SDL) Describe various methods of treatment of hospital waste.
100	111uay, 31 Way, 2024	SU7.2 Discuss the principles and steps of		FR 1.43, 1.33-3GD		nospitai waste.
169	Saturday, 1 June, 2024	clinical research in General Surgery	AETCOM	4.18 Medical Negligence		Family Adoption Program
170	Sunday, 2 June, 2024			WEEKLYOFF		

171	Monday, 3 June, 2024	PA 23.1 SDL Describe abnormal urinary findings in disease states andidentify and describe common urinary abnormalities in a clinical specimen		MI 4.1, 4.2, 4.3: Infective syndromes of skin and soft tissue (L)		PA 19.7 DOAP: Identify and describe the gross specimen of an enlarged spleen		
172	Tuesday, 4 June, 2024	PH-1.42: Cephalosporins- (L)		PA 23.2 SGD Describe abnormal findings in body fluids in various disease States		FM 1.9 Dental Examination DOAP	MI 1.1: Hydatid disease and other parasitic infections of liver (SGD)	
173	Wednesday, 5 June, 2024	PH-1.42 Cephalosporins-2		PA 23.3 SGD Describe and interpret the abnormalities in a panel containing semen analysis, thyroid function tests, renal function tests or liver function tests	LUNCH BREAK	MI 3.8, 8.15: Viral hepatitis, parasites causing liver infection (P), Batch A/B		
				PA 24.1 L: Describe the etiology, pathogenesis, pathology and clinical features of oral cancers		PH5.4 Explain to the patient the relationship between cost of treatment		
174	Thursday, 6 June, 2024 Friday, 7 June, 2024	MI 4.3: Staphylococcal infections (L) 23.1 :Discuss and describe the methods of nutritional assessment in an adult and calculation of caloric requirements during illnesses 23.2 :Discuss and describe the causes and consequences of protein caloric malnutrition in the hospital		PH-1.42 Cephalosporins & penicillin		CM 14.3 Describe law	s related to hospital waste	
176	Saturday, 8 June, 2024			2nd SATURDAYOFF				
177	Sunday, 9 June, 2024			WEEKLYOFF				
178	Monday, 10 June, 2024	IA 2	IA 2	IA 2		IA 2	IA 2	
179	Tuesday, 11 June, 2024	IA 2	IA 2	IA 2		IA 2	IA 2	
180	Wednesday, 12 June, 2024	IA 2	IA 2	IA 2	I HNOH DDE 4 17	IA 2	IA 2	
181	Thursday, 13 June, 2024	IA 2	IA 2	IA 2	LUNCH BREAK	IA 2	IA 2	
182	Friday, 14 June, 2024	IA 2	IA 2	IA 2		IA 2	IA 2	
183	Saturday, 15 June, 2024	IA 2	IA 2	IA 2		IA 2	IA 2	
184	Sunday, 16 June, 2024			WEEKLYOFF				
185	Monday, 17 June, 2024			E I D - U L - A Z H A*				
186	Tuesday, 18 June, 2024			<u> </u>				
187	Wednesday, 19 June, 2024							
188	Thursday, 20 June, 2024		CHMMEDWACATION					
189	Friday, 21 June, 2024			SUMMERVACATION	•			
190	Saturday, 22 June, 2024							
191	Sunday, 23 June, 2024							

192	Monday, 24 June, 2024	PA 24.2 L: Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease	MI 4.3: Streptococcal infections pertaining to skin (L)		describe the princi demonstrate the st	rate the indications, ples, enumerate and teps of compatibility tting
193	Tuesday, 25 June, 2024	PH1.42: Aminoglycosides- 1 (L)	PA 24.4 L: Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach		FM 1.9 Dental Examination DOAP	MI 4.3: Leprosy (SGD)
194	Wednesday, 26 June, 2024	PH 1.42: Aminoglycosides- 2 – (L)	PA 24.5 SGD: Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine	LUNCH BREAK	diagnosis of sta	5: Gram staining, Lab aphylococcal and ctions (P) Batch A/B
195	Thursday, 27 June, 2024	MI 4.1: Gas gangrene and tetanus (L)	PA 24.6 L: Describe and etiology and pathogenesis and pathologic and distinguishing features of Inflammatory bowel disease		caution in pro likely to produc recommen	un understanding of the escribing drugs e dependence and id the line of agemen
196	Friday, 28 June, 2024	OG 13.1 (B) Monitoring of labour and partogram/ LCG	PH1.42-(SGD) Aminoglycosides		CM 15.2 (Lecture) Demental health disorder	scribe warning signals of CM 15.2 (SGD)Describe mental health disorder
197	Saturday, 29 June, 2024	Revision	FM 4.20 legal provisions		Family Ado	ption Program
198	Sunday, 30 June, 2024		WEEKLYOFF	1	1	
199	Monday, 1 July, 2024	PA 24.7 L: Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon	MI 4.3: Viral exanthems 1 (L)		abnormalities in semen analysis, th renal func	be and interpret the a panel containing yroid function tests, tion tests or tion tests (I)
200	Tuesday, 2 July, 2024	PH:1.42: Macrolides- L	PA 25.1 SGD (IL): Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia		FM 1.9 MCCD DOAP	MI 4.3: Tissue nematode infections of skin and soft tissue (SGD)
201	Wednesday, 3 July, 2024	PH1.42:Fluroquinlones- (L)	PA 25.2 SGD (IL): Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences.	LUNCH BREAK		ections due to non Batch A/B, SGD

202	Thursday, 4 July, 2024	MI 4.3: Viral exanthems 2 (L) 23.4:Enumerate the indications for enteral and parenteral nutrition in critically ill		PA 25.3 SGD (IL): Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis.		& patients aspects of drug to dependence a	bility to educate public about various use including drug and OTC drugs
203	Friday, 5 July, 2024	patients		PH1.42:Fluro-SGD			program
204	Saturday, 6 July, 2024	Revision	AETCOM	FM 4.19 Consent		and ethica	understanding of the legal all aspects of bing drugs
205	Sunday, 7 July, 2024			WEEKLYOFF			
206	Monday, 8 July, 2024	PA 25.4 L: Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis		MI 4.3: Superficial, subcutaneous fungal infections (L)		abnormalities in semen analysis, th renal func	be and interpret the a panel containing yroid function tests, tion tests or ion tests(II)
207	Tuesday, 9 July, 2024	PH1.43-Sulphonamides – (L)		PA 25.5 L: Describe the etiology, pathogenesis and complications of portal hypertension Diseases of gall bladder		FM 1.9 MCCD DOAP	MI 8.5, 8.6, 8.7: Hospital acquired infections (SGD)
208	Wednesday, 10 July, 2024	PH1.43-Cotrimoxazole-(L)		PA 26.1 L: Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia	LUNCH BREAK	MI 4.3, 8.15: SSTI due to superficial and subcutaneous fungi (P) Batch A/B, cutaneous & mucosal candidiasis; Penicilliosis (SGD)	
209	Thursday, 11 July, 2024	MI 5.1: Infective syndromes of CNS (L)		PA 26.2 SGD: Describe the etiology, gross and microscopic appearance and complications of lung abscess			tion of neuro-muscular ng agents
210	Friday, 12 July, 2024	OG 13.1 (B) Monitoring of labour and partogram/ LCG		PH1.44: dugs used in MDR and XDR Tuberculosis - SGD		of various nutrients requirements accordi	ribe the common sources and special nutritional ng to age, sex, activity, al conditions
211	Saturday, 13 July, 2024			2nd SATURDAYOFF			
212	Sunday, 14 July, 2024			WEEKLYOFF			

213	Monday, 15 July, 2024	PA 26.3 L: Define and describe the etiology, types, pathogenesis, stages, morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis		MI 5.1: Agents of pyogenic meningitis (L)		PA 24.1 : DOAP Describe and identify microscopic features of plepmorphic adenoma	
214	Tuesday, 16 July, 2024	PH1.48-Drug treatment of UTI- (L)		PA 26.4 L: Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis	LUNCH BREAK	FM 1.9 Toxicology Specimen SGD	MI 5.1: Agents of aseptic meningitis 1 (SGD)
215	Wednesday, 17 July, 2024		I	MUHARRAM*/ASHUR	R A*		
				PA 26.5 SGD: Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complications of Occupational lung	LUNCH BREAK	MI 1.2, 5.3, 8.15: Gram staining and agents of pyogenic meningitis (P)	MI1.6 Describe the mechanisms of drug resistance, methods of antimicrobial susceptibility testing and monitoring of antimicrobial
216	Thursday, 18 July, 2024	PH1.46-ATT- (L)		disease N		Batch A/B & SGD	therapy
217	Friday, 19 July, 2024	23.3:Discuss and describe the aetiology, causes, clinical manifestations, complications, diagnosis and management of common vitamin Deficiencies		PH 1.55: Side effects of Antileprotics –(SGD)		correct method of pe assessment of individ	ibe and demonstrate the erforming a nutritional duals, families and the the appropriate method
218	Saturday, 20 July, 2024	Assessment	AETCOM	FM 2.1 Death and its types, 2.2 Natural and Unnatural deaths, 2.3 sudden natural death		Family Ado	ption Program
219	Sunday, 21 July, 2024			WEEKLYOFF		,	
220	Monday, 22 July, 2024	PA 26.6 L : Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, stages, morphology, microscopic appearance, metastases and complications of tumors of the lung and pleura		MI 5.2: Viral encephalitis 1 (L)			scribe and identify the ares of peptic ulcer .
221	Tuesday, 23 July, 2024	PH1.46-ATT- (L)		PA 26.7 L: Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, morphology, microscopic appearance and complications of mesothelioma		FM 1.9 Toxicology Specimen SGD	MI 5.1: Agents of aseptic meningitis 2 (SGD)

222	Wednesday, 24 July, 2024	PH1.46-Anti Leprotics- L	PA 27.1 SGD: Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis PA 27.2 SGD: Describe the etiology, dynamics, pathology types and complications of aneurysms including	LUNCH BREAK	A/B; MI 1.1 & 4.1: (So MI3.3 Describe the e and discuss the clinical course, the	e meningitis (P), Batch : Neurocysticercosis GD) nteric fever pathogens ne evolution of le laboratory diagnosis ases caused		
223	Thursday, 25 July, 2024	MI 5.2: Viral encephalitis 2 (L)	aortic aneurysm			them		
224	Friday, 26 July, 2024	OG 13.1 (C) Conduct of labour and management of 3rd stage of labour	PH1.47: Prophylaxis and Management of MalariaSGD		CM 5.3(Lecture) Define and describe common nutrition-related health disorders (including macro-PEM, Micro-iron, Zn, iodine, Vit. A), their control and management			
225	Saturday, 27 July, 2024		4th S A T U R D A Y O F F					
226	Sunday, 28 July, 2024		WEEKLYOFF	T				
227	Monday, 29 July, 2024	PA 27.3 SGD: Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure	MI 1.1, 4.1: Tetanus and botulism (L)		PA 24.5 : DOAP Describe and identify the microscopic features of Tuberculosis of intestine.			
228	Tuesday, 30 July, 2024	PH1.47- drugs used in Malaria,Antimalarial drugs (L)	PA 27.4 L: Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of rheumatic fever		FM 3.14 SEXUAL OFFENCE MICROSCOPIC EXAMINATION SEMEN SGD	MI 5.2: Parasites causing encephalitis (SGD)		
229	Wednesday, 31 July, 2024	PH1.47- ACTs (L)	PA 27.5 L: Describe the epidemiology, risk factors, etiology, pathophysiology, pathology, pathology, presentations, gross and microscopic features, diagnostic tests and complications of ischemic heart disease	LUNCH BREAK	MI 1.2: AFB Stai	ning (P) Batch A/B		

230	Thursday, 1 August, 2024	MI 6.1: Infective syndromes of Respiratory tract (L)		PA 27.6 SGD: Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of infective endocarditis		food poisoning pathogenesis, clinical diag	e causative agents of and discuss the course and laboratory nosis	
231	Friday, 2 August, 2024	16.1:Describe and discuss the aetiology of acute and chronic diarrhea including infectious and non-infectious causes 16.6:Distinguish between diarrhea and dysentery based on clinical features		PH1.47:SGD Management of complicated malaria		nutritional surveillance, education and rehabili sociocultural factors. On the methods of nutri principles of nutrit rehabilitation in the c	principles of nutritional tation in the context of CM 5.5 (SDL) Describe itional surveillance, ional education and ontext of sociocultural tors	
232	Saturday, 3 August, 2024 Sunday, 4 August, 2024	SU8.1 Discuss the principles of Ethics as it pertains to General Surgery SU8.2 Demonstrate Professionalism and empathy to the patient undergoing General Surgery	AETCOM	FM 2.4 Human organ transplantation 2.5 Moment and modes of death WEEKLYOFF		MI3.6 Describe the etio-pathogenesis of Acid Peptic Disease (APD) and the clinical course. Discuss the diagnosis and management of the causative agent of APD		
233	Suliday, 4 August, 2024			WEEKEIGFF		PA	24.4,	
234	Monday, 5 August, 2024	PA 27.7 SGD: Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of pericarditis and pericardial effusion		MI 6.1: Diphtheria (L)		Gross : Carcinoma of the stomach, Slide : Carcinoma of the stomach,		
235	Tuesday, 6 August, 2024	PH1.47-AntiAmoebic drugs-L		PA 27.9 L: Classify and describe the etiology, types, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of cardiomyopathies N		FM 3.14 SEXUAL OFFENCE MICROSCOPIC EXAMINATION SEMEN SGD	MI 6.1: Parainfluenza and RSV (SGD)	
236	Wednesday, 7 August, 2024	PH1.47-AntiFungal drugs-1 (L)		PA 27.10 SGD: Describe the etiology, pathophysiology, pathology features and complications of syphilis on the cardiovascular system	LUNCH BREAK	URTI (P) Batch A/B	ab gram staining& ; SGD: Streptococcal tions	
237	Thursday, 8 August, 2024	MI 6.1: Viral URTI 1 (L)		PA 28.1 SDL : Describe the normal histology of the kidney		application cycle	e mode of action & of commonly used ad rodenticides	

241	Monday, 12 August, 2024	pathology, morphology, clinical and laboratory and urinary findings, complications of renal failure		MI 6.1: Tuberculosis 1 (L) PA 28.3 L : Define and describe the etiology,		Carcinoma	oss : of the colon ma of the colon
242	Tuesday, 13 August, 2024	PH1.47-Anti Fungal drugs 2- (L)		precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of acute renal failure	LUNCH BREAK	FM 2.23 DROWNING , MICROSCOPIC EXAMINATION DIATOM SGD	MI 6.1: Viral URTI: Rhinovirus, Adenovirus and EBV
243	Wednesday, 14 August, 2024	PH1.48: Anti-viral drugs -1(L		PA 28.4 L: Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings progression and complications of chronic renal failure		MI 6.3: Sputum gram staining (P) Batch A/B; MI 6.1: Agents of typical pneumonia (SGD)	CM19.1 Define and describe the concept of Essential Medicine List (EML)
244	Thursday, 15 August, 2024	TITI. 10.7 Inti vital diago 1(D		INDEPENDENCEDA	Y	pheamonia (502)	micure 2150 (21112)
245	Friday, 16 August, 2024	16.2 :Describe and discuss the acute systemic consequences of diarrhea including its impact on fluid balance 16.3 :Describe and discuss the chronic effects of diarrhea including malabsorption		SGD) Intestinal helminthesiasis	LUNCH BREAK	SGD Describe and disc methods of food forti	Frood Hygiene CM 5.8: cuss the importance and fication and effects of d adulteration
246	Saturday, 17 August, 2024 Sunday, 18 August, 2024	SU8.3 Discuss Medico-legal issues in surgical practice	AETCOM	FM 2.6, presumptions, 2.7 suspended animation, 2.10 Time since death WEEKLYOFF		Family Ado	otion Program
2		PA 28.5 L: Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis		MI 6.1: Tuberculosis 2		CERTIFIABLE SKILL PA 25.6 DOAP Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non- obstructive jaundice based on clinical features and liver function test.	

249	Tuesday, 20 August, 2024	PH1.48: Anti-viral drugs-2(L)	PA 28.5 L: Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis (II)	LUNCH BREAK	FM 2.28 DOAP session of ossification centres, Hydrostatic test. MI 6.1: Fungal and parasitic agents causing LRTI (SGD)	
250	Wednesday, 21 August, 2024	PHARMA	PA 28.6 L: Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of IgA nephropathy		MI 1.2 & 6.3: Lab diagnosis of TB and AFB staining (P), Batch A/B; MI 6.1: Agents of atypical pneumonia (SGD)	
251	Thursday, 22 August, 2024	MI 6.1: Sars Cov and Mers Cov (L)	PA 28.7 L: Enumerate and describe the findings in glomerular manifestations of systemic disease		CM19.2 Describe roles of essential medicine in primary health care	
252	Friday, 23 August, 2024	OG 19.1 Puerperium	PH1.48: drugs used in :UTI/ STD SGD CM 9.1(Lecture) Define and descr principles of Demography, Demography Vital statistics			
253	Saturday, 24 August, 2024		4th S A T U R D A Y O F F			
254	Sunday, 25 August, 2024		WEEKLYOFF			
255	Monday, 26 August, 2024		JANMASHTAMI	T		
256	Tuesday, 27 August, 2024	PH1.48-Anti HIV- Drugs (L)	PA 28.8 SGD : Enumerate and classify diseases affecting the tubular interstitium		FM2.29 Demonstrate respect to the directions of courts, while appearing as witness for recording of evidence under oath or affirmation, examination in chief, cross examination DOAP MI 8.8: Bacteriology of air, milk and water and surface (SGD)	
257	Wednesday, 28 August, 2024	PH1.48-Anti HIV-HAART regimen (L)	PA 28.9 SGD: Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of acute tubular necrosis		PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes Slide: Atheroma MI 1.3: Stool microscopy (P) Batch A/B; MI 1.1: Infective syndromes of eye SGD	

258	Thursday, 29 August, 2024	MI 7.3: Normal commensals of genitourinary tract and UTI (L)	PA 28.10 SGD: Describe the etiology pathogenesis pathology laboratory findings, distinguishing features progression and complications of acute and chronic pyelonephritis and reflux nephropathy	LUNCH BREAK		interfeit medicine and vention
259	Friday, 30 August, 2024	16.11 :Enumerate the indications for stool cultures and blood cultures in patients with acute diarrhea 16.12 :Enumerate and discuss the indications for further investigations including antibodies, colonoscopy, diagnostic imaging and biopsy in the diagnosis of chronic diarrhea	PH1.48-Anti HIV drugs (SGD)		principles of Demograp	ine and describe the ohy, Demographic cycle, tatistics
260 261	Saturday, 31 August, 2024 Sunday, 1 September, 2024	SU9.1 Choose appropriate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in a surgical patient	FM 2.8 Postmortem changes WEEKLYOFF		Family Adop	otion Program
261	Sunday, 1 September, 2024	PA 28.11 L : Define classify and describe	WEEKLYOFF			
0.50		the etiology, pathogenesis pathology, laboratory, urinary findings, distinguishing features progression and complications of vascular disease of the			urinary findings in identify and describ	escribe abnormal a disease states and be common urinary
262	Monday, 2 September, 2024	kidney	MI 7.2: Syphilis (L) PA 28.12 L: Define classify and describe the genetics, inheritance, etiology, pathogenesis,		abnormalities in a	a clinical specimen
263	Tuesday, 3 September, 2024	PH1.49: Anticancer drugs 1- L	pathology, laboratory, urinary findings, distinguishing features, progression and complications of cystic disease of the kidney		FM2.11 Describe and discuss autopsy procedures including post-mortem examination, different types of autopsies SGD	MI 7.1,7.2: Gonococcal and non gonococcal urethritis (SGD)

264	Wednesday, 4 September, 2024	PH1.49: Ant-cancer drugs 2- L		PA 28.13 SGD: Define classify and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features progression and complications of renal stone disease and obstructive uropathy	LUNCH BREAK		ning UTI agents (P) nts of UTI (SGD)
265	Thursday, 5 September, 2024	MI 7.2: Agents of vaginal discharge and genital warts (L)		PA 28.14 L: Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features, progression and spread of renal tumor		FM4.11 Describe a	nd discuss euthanasia
		16.13:Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy for parasitic (Amebiasis, Giardiasis) causes of diarrhea 16.14:Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy for bacterial and viral diarrhea				CM 9.2(SGD) Define demographic indices in	, calculate and interpret acluding birthrate, death
266	Friday, 6 September, 2024			PH 1.23-SGD		rate, fer	tility rate
267	Saturday, 7 September, 2024	SU9.2 Biological basis for early detection of cancer and multidisciplinary approach in management of cancer	AETCOM	FM 2.9 Postmortem changes			al and ethical issues in m cell research
268	Sunday, 8 September, 2024			WEEKLYOFF		_	
269	Monday, 9 September, 2024	PA 28.15 L : Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies N		MI 7.2: Agents of genital ulcer 2:LGV, GI, HSV, soft chancre (L)		PA : GROSS : chron	tical : 28.10 ic pyelonephritis c pyelonephritis
270	Tuesday, 10 September, 2024	PH1.50: Immunomodulators- L		PA 28.16 L : Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumor		FM2.12 Describe the legal requirements to conduct post- mortem examination and procedures to conduct SGD	MI 1.1: Infective syndromes of ear, nose and oral cavity (SGD)

271	Wednesday, 11 September, 202	PH1.50: - Immunomodulators L	PA 29.1 L: Classify testicular tumors and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumors	LUNCH BREAK	MI 1.2, 7.1, 7.2: Ste slides of bacterial va Batcl	ginosis, neisseria (P)
272	Thursday, 12 September, 2024	MI 8.5, 8.6: HAIs , surveillance and prevention bundles (L)	PA 29.2 SGD: Describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the penis			and discuss ethical ect for autonomy, eneficence & justice
			PH1.50: Management of organ transplant rejection		CM 9.3(Lecture) Enum causes of declining sex	nerate and describe the
273	Friday, 13 September, 2024	OG 17.1 ,17.3 - Lactation	(SDL)		health im	
274	Saturday, 14 September, 2024		2nd SATURDAYOFF	י		
275	Sunday, 15 September, 2024		WEEKLYOFF			
276	Monday, 16 September, 2024		EID-MILAD-UN-NABI	(SAW)*		
277	Tuesday, 17 September, 2024	PH 1.17: Local Anesthetics- 1 Lect	PA 29.3 L : Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, urologic findings & diagnostic tests of benign prostatic hyperplasia		FM2.14 Describe and discuss examination of clothing, preservation of viscera on postmortem examination for chemical analysis SGD	MI 8.1: Zoonotic infections (SGD)
278	Wednesday, 18 September, 202	PH 1.17: Local Anesthetics-2 Lect	PA 29.4 L : Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate	LUNCH BREAK	PA 2	S: RCC

279	Thursday, 19 September, 2024	MI 1.6: Antimicrobial stewardship and rational use of antibiotics (L)		PA 29.5 L: Describe the etiology, pathogenesis, pathology and progression of prostatitis			ath – Hippocrates, ruta and procedure ation of Oath
280	Friday, 20 September, 2024	16.15 :Distinguish based on the clinical presentation Crohn's disease from Ulcerative Colitis 16.16 :Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy including immunotherapy 16.17:Describe and enumerate the indications for surgery in inflammatory bowel disease		PH 1.17: LA- SGD			erate and describe the ratio and its social and plications
		SU9.3 Communicate the results of surgical investigations and counsel the patient		FM 2.20 Introduction to mechanical asphyxia, 2.21			
281	Saturday, 21 September, 2024	appropriately	AETCOM	Hanging and strangulation		Family Adop	tion Program
282	Sunday, 22 September, 2024			WEEKLYOFF			
283	Monday, 23 September, 2024	PA 30.1 L : Describe the epidemiology, pathogenesis, etiology, pathology, screening, diagnosis and progression of carcinoma of the cervix		MI 8.1: TORCH infections (L)		Slide : BPH	inoma testis
284	Tuesday, 24 September, 2024	PH1.18-Pre-Anes agents- L		PA 30.2 L : Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of carcinoma of the endometrium		FM2.35 Demonstrate professionalism while conducting autopsy in medicolegal situations, interpretation of findings and making inference/opinion DOAP	MI 8.2: Opportunistic infections (SGD)
285	Wednesday, 25 September, 202	PH1.18-General Anesthetics- Lect		PA 30.3 SGD: Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of carcinoma of the leiomyomas and leiomyosarcoma	LUNCH BREAK		ng revision (P) Batch ats of bioterrorism GD)
286	Thursday, 26 September, 2024	MI 8.3: Organisms with oncogenic potential 1 (L)		PA 30.4 L : Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumor		FM4.23 Describe the of Geneva an	modified Declaration d its relevance

287	Friday, 27 September, 2024	OG 21.1 Contraception 1		SDL IV Anaesthetics		CM 9.4(Lecture): Enumerate causes and consequences explosion and population decomposition decomposit	of population
288	Saturday, 28 September, 2024	od 2111 contraception1		4th SATURDAYOFF		expression and population d	ynames of mola.
289	Sunday, 29 September, 2024			WEEKLYOFF			
290	Monday, 30 September, 2024	PA 30.5 SGD : Describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of gestational trophoblastic neoplasms		MI 8.3: Organisms with oncogenic potential 1 (L)	LUNCH BREAK	Practical: PA 30.1 Gross: CA Co CA Endometr Slide: SCC C Proliferative endo Secretory endon	ervix rium ervix ometrium
291	Tuesday, 1 October, 2024	PH1.18-Gen Anesthetics- Lect		PA 30.6 L : Describe the etiology and morphologic features of cervicitis		20111	1.1: Vector borne fections (SGD)
292	Wednesday, 2 October, 2024			GANDHIJAYANTI			
293	Thursday, 3 October, 2024	MI 8.16: National health programs (L)		PA 30.7 SGD: Describe the etiology, hormonal dependence, features and morphology of endometriosis N		MI1.2: Stool microscopy revision (P) all batchesMI	M4.25 Clinical search & Ethics: Discuss human sperimentation cluding clinical trials
294	Friday, 4 October, 2024	15.1:Enumerate, describe and discuss the aetiology of upper and lower GI bleeding 15.2:Enumerate, describe and discuss the evaluation and steps involved in stabilizing a patient who presents with acute volume loss and GI bleed 15.3:Describe and discuss the physiologic effects of acute blood and volume loss 15.6:Distinguish between upper and lower gastrointestinal bleeding based on the clinical features 15.10:Enumerate the indications for endoscopy, colonoscopy and other imaging procedures in the investigation of Upper GI bleeding 15.9:Choose and interpret diagnostic tests based on the clinical diagnosis including stool examination, occult blood, liver function tests, H.pylori test.		PH 1.19: Satus EpilepticusSGD	LUNCH BREAK	CM 9.5(Lecture): Describe population con	
277	113ay, 1 000001, 2027	SU11.1 Describe principles of Preoperative assessment. SU11.2 Discuss the principles of general,				• •	
295	Saturday, 5 October, 2024	regional, and local Anaesthesia.	AETCOM	FM 2.22 Traumatic asphyxia, sexual asphyxia		FM4.26 Discuss the constitution ethical commit	
296	Sunday, 6 October, 2024			WEEKLYOFF	1		

297	Monday, 7 October, 2024	PA 30.8 SGD : Describe the etiology and morphologic features of adenomyosis N	MI 8.13: Rational use of microbiological investigations (SGD)		Practical : PA 30.3, PA 30.4 Gross : Serous & Mucinous tumour Leiomyoma Slide : Serous & Mucinous tumour Leiomyoma
298	Tuesday, 8 October, 2024	PH1.19: Sedatives & Hypnotics-(L)	PA 30.9 L : Describe the etiology, hormonal dependence and morphology of endometrial hyperplasia		REVISION REVISION
299	Wednesday, 9 October, 2024	PH 1.19: Anti Epileptic drugs- (L)	PA 31.1 SGD: Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease	LUNCH BREAK	MICROBIOLOGY SPOTS REVISION (P)
			PA 31.2 L : Classify and describe the epidemiology, pathogenesis, classification, morphology, prognostic factors, hormonal dependency, staging and spread of		FM4.27Describe and discuss Ethical
300	Thursday, 10 October, 2024	MI 8.12: Confidentiality pertaining to patient identity (SGD)	carcinoma of the breast		Guidelines for Biomedical Research on Human Subjects & Animals
301	Friday, 11 October, 2024	OG 21.2 Contraception 2	PH1.52 Tt of poisoningSGD		CM 9.5(SGD): Describe the methods of population control
302	Saturday, 12 October, 2024		DUSSHERA		
303	Sunday, 13 October, 2024		WEEKLYOFF		
304	Monday, 14 October, 2024	PA 31.4 SGD: Enumerate and describe the etiology, hormonal dependency and pathogenesis of gynecomastia N	MI 8.4: Emerging and re-emerging infections (L)		Practical : PA 31.1, PA 31.2, Gross : Fibroadenoma CA Breast Slide : Fibroadenoma Adenocarcinoma Breast

				PA 32.1 SGD: Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of		
305	Tuesday, 15 October, 2024	PH 1.19: Anti Epileptic drugs- (L)		thyroid swellings		REVISION REVISION
				PA 32.2 SGD: Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and		
				imaging features and		MICRO (P)CULTURE MEDIA AND
306	Wednesday, 16 October, 2024	PH1.19-Anti Depressants- 1(L)		course of thyrotoxicosis	LUNCH BREAK	BIOCHEMICALS REVISION, BATCH A/B
				PA 32.3 SGD: Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of		
307	Thursday, 17 October, 2024	REVISION: MI 5.1: Fungal infections of CNS (SGD)		thyrotoxicosis/ hypothyroidism.		FM8.1 Describe the history of Toxicology
		9.2:Describe and discuss the morphological characteristics, aetiology and prevalence of each of the causes of anemia 9.12:Describe, develop a diagnostic plan to determine the aetiology of anemia 9.7:Describe and discuss the meaning and utility of various components of the hemogram 9.8:Describe and discuss the various tests for iron deficiency 9.11;Describe the indications and interpret				, 0,
		the results of a bone marrow aspirations and biopsy		PH1.19-Anti DepressantsSGD		CM 9.6(SDL): Describe the National Population
308	Friday, 18 October, 2024	CIII 4 Discover the indications on 1				Policy
309	Saturday, 19 October, 2024	SU11.4 Discuss the indications and principles of day care General Surgery	AETCOM	FM 2.23 Drowning		Family Adoption Program
310	Sunday, 20 October, 2024			WEEKLYOFF		
		PA 32.4 L : Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features, complications and progression of diabetes		MI 8.5, 8.6: REVISION STANDARD		PRACTICAL PA 32.1 & PA 32.3 Gross: Colloid Goitre Papillary CA thyroid Slide: Colloid Goitre,
311	Monday, 21 October, 2024	mellitus		PRECAUTIONS (L)		

			D4 00 5 00D			
			PA 32.5 SGD:			
			Describe the etiology,			
			genetics,			
			pathogenesis, manifestations,			
			laboratory and morphologic features			
			of			
			hyperparathyroidism			REVISION: BMW
312	Tuesday, 22 October, 2024	PH1.19-Anti Depresants- 2 (L)	N		REVISION	AND HAND HYGIENE
312	Tuesday, 22 October, 2024	FH1.19-Allu Deplesalus- 2 (L)	• • • • • • • • • • • • • • • • • • • •		REVISION	HIGIENE
			PA 32.6 SGD :			
			Describe the etiology,	LUNCH BREAK		
			pathogenesis,			
			manifestations,			
			laboratory, morphologic features,			
			complications and			
			metastases of			
313	Wadaaadaa 22 Ootabaa 2024	DIII 10 Ant Dough sting I	pancreatic cancer N		MICDO (D), AED C	FAINING DEVICION
313	Wednesday, 23 October, 2024	PH1.19-Ant-Psychotics- L	·		MICRO (P): AFB 3	FAINING REVISION
			PA 32.7 SGD:			
			Describe the etiology,			
			pathogenesis,			
			manifestations,			
			laboratory,			
			morphologic features,		EMOAD C. 4	, m : 1
			complications of			terms Toxicology,
314	Thursday, 24 October, 2024	REVISION	adrenal insufficiency N			cology, Clinical and poison
314	Thursday, 24 October, 2024	REVISION	IV.			*
						an and recommend a
			PH1.19-SGD psychedelics,			ndividuals and families lability of foods and
315	Friday, 25 October, 2024	OG 21.3 Contraception 3	drugs used for criminal offences			ic status.
316	Saturday, 26 October, 2024	od 2115 contraception 5	4th S A T U R D A Y O F F		cconom	ne status.
317			WEEKLYOFF			
317	Sunday, 27 October, 2024		WEEKLIUFF		DD 4 G	mr a . r
						TICAL
						33.2
						oss:
		PA 32.8 SGD : Describe the etiology,			Usteosar	coma,GCT
		pathogenesis, manifestations,			ÇI:	de:
		laboratory, morphologic features,				ae : CT
318	Monday 28 October 2024	complications of Cushing's syndromeN	REVISION		G	
310	Monday, 28 October, 2024	Tomphodicino or custing soynaromen				
			PA 32.9 SGD:			
			Describe the etiology,			
			pathogenesis,			
			manifestations,			
			laboratory and			
			morphologic features			
210	Tuesday 20 October 2024	DH1 10 Ant Monico drugs I	of adrenal neoplasm N		REVISION	REVISION
319	Tuesday, 29 October, 2024	PH1.19-Ant-Maniac drugs-L	IV		KE VISION	REVISION

320	Wednesday, 30 October, 2024 Thursday, 31 October, 2024	PH1.19-Anti Parkinsonian Drugs- 1(L) REVISION		PA 33.1 L : Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis PA 33.2 L : Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumor	LUNCH BREAK	MICRP (P):GRAM STAINING REVISION FM8.3 Describe the various types of poisons, Toxicokinetics & Toxicodynamics and diagnosis of poisoning in living and dead
322	Friday, 1 November, 2024			DEEPAWALI		-
323 324	Saturday, 2 November, 2024 Sunday, 3 November, 2024	SU11.5 Describe principles of providing post-operative pain relief and management of chronic pain.	AETCOM	FM 2.24 Thermal death WEEKLYOFF	LUNCH BREAK	FM8.4 Describe the Laws in relations to poisons including NDPS Act, Medico-legal aspects of poisons
325	Monday, 4 November, 2024	PA 33.3 L : Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft tissue tumors		REVISION PA 33.4 SGD: Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features		PA 35.3: CERTIFIABLE SKILL Identify the etiology of meningitis based on given CSF parameters
326	Tuesday, 5 November, 2024	PH1.19- Anti Parkinsonian Drugs- 2 (L)		and complications of Paget's disease of the bone		REVISION REVISION

327	Wednesday, 6 November, 2024	PH1.19-Drugs for Alzheimers Disease- (L)	PA 33.5 SGD: Classify and describe the etiology, immunology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of rheumatoid arthritis	LUNCH BREAK	MICRO (P): GRAM STAINING REVISION	
220	The 1 7 No. 2024	DEWISION	PA 34.1 L: Describe the risk factors pathogenesis, pathology and natural history of squamous cell carcinoma of the skin		FM8.5 Describe Medico-legal autopsy in cases of poisoning including preservation and dispatch of viscera for	
328	Thursday, 7 November, 2024 Friday, 8 November, 2024	REVISION OG 22.1 Physiological discharge	PH1.19-SGD Drug Regulations, acts and other legal aspects		chemical analysis CM:5.3(DOAP) Plan and recommend a suitable diet for the individuals and families based on local availability of foods and economic status, etc in a simulated environment	
330	Saturday, 9 November, 2024		2nd SATURDAYOFF			
331	Sunday, 10 November, 2024		WEEKLYOFF			
332	Monday, 11 November, 2024	PA 34.2 L: Describe the risk factors pathogenesis, pathology and natural history of basal cell carcinoma of the skin	REVISION		CARDS & INSTRUMENTS	
333	Tuesday, 12 November, 2024	PH1.19.Opiods-1 (L)	PA 34.3 L: Describe the distinguishing features between a nevus and melanoma. Describe the etiology, pathogenesis, risk factors morphology clinical features and metastases of melanoma		REVISION REVISION	
334	Wednesday, 13 November, 202	PH1.19.Opiods-2 (L)	PA 35.1 L : Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis	LUNCH BREAK	MICRO (P): REVISION	
335	Thursday, 14 November, 2024	REVISION	PA 35.2 L : Classify and describe the etiology, genetics, pathogenesis, pathology, presentation sequelae and complications of CNS tumors		FM8.6 Describe the general symptoms, principles of diagnosis and management of common poisons encountered in India	

336	Friday, 15 November, 2024		(GURUNANAK'S BIRTHI	DAY		
337	Saturday, 16 November, 2024	SU11.6 Describe Principles of safe General Surgery	AETCOM	FM 2.25 Burns WEEKLYOFF	LUNCH BREAK	CM:5.3(DOAP) Plan an diet for the individuals local availability of food etc in a simulate	and families based on ds and economic status,
338	Sunday, 17 November, 2024			WEEKLYOFF			
339	Monday, 18 November, 2024	PA 36.1 SGD: Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma		REVISION		CARDS & IN	STRUMENTS
340	Tuesday, 19 November, 2024	PH 1.20: Alcohol - (L)		REVISION		REVISION	REVISION
341	Wednesday, 20 November, 202	PH 1.20: acute and chronic ethanol intake-		REVISION	LUNCH BREAK	MICRO (P): REVISION FM8.7 Describe simple Bedside clinic tests to detect poison/drug in a	
342	Thursday, 21 November, 2024	REVISION		REVISION			ody fluids
343	Friday, 22 November, 2024	OG 22.2 Pathological discharge and Syndromic management		PH1.19-SGD Opioid antagonists and Management of morphine poisoning		Formative Assessment	
344	Saturday, 23 November, 2024			4th SATURDAY OFF			
345	Sunday, 24 November, 2024			WEEKLYOFF			
346	Monday, 25 November, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
347	Tuesday, 26 November, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
348	Wednesday, 27 November, 202	IA 3	IA 3	IA 3	LUNCH BREAK	IA 3	IA 3
349	Thursday, 28 November, 2024	IA 3	IA 3	IA 3	LUNCH BREAK	IA 3	IA 3
350	Friday, 29 November, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
351	Saturday, 30 November, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
352	Sunday, 1 December, 2024			WEEKLYOFF			
353	Monday, 2 December, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
354	Tuesday, 3 December, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
355	Wednesday, 4 December, 2024	IA 3	IA 3	IA 3	LUNCH BREAK	IA 3	IA 3
356	Thursday, 5 December, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
357	Friday, 6 December, 2024	IA 3	IA 3	IA 3		IA 3	IA 3
358	Saturday, 7 December, 2024						
359	Sunday, 8 December, 2024						
360	Monday, 9 December, 2024						
361	Tuesday, 10 December, 2024						
362	Wednesday, 11 December, 202		DDED	ARATORY			
363	Thursday, 12 December, 2024		FREP	ANAIUNI	LLAYL		
364	Friday, 13 December, 2024						
365	Saturday, 14 December, 2024						
366	Sunday, 15 December, 2024						
367	Monday, 16 December, 2024						
368	Tuesday, 17 December, 2024						

369	Wednesday, 18 December, 202	_				
370	Thursday, 19 December, 2024		EXAMINATION	& RESI		
371	Friday, 20 December, 2024					
372	Saturday, 21 December, 2024					
373	Sunday, 22 December, 2024		WEEKLYOFF			
374	Monday, 23 December, 2024		EXAMINATION 8	- DECIH	T	
375	Tuesday, 24 December, 2024		EXAMINATION	KESUL	<i>i</i> 1	
376	Wednesday, 25 December, 202		CHRISTMAS			
377	Thursday, 26 December, 2024	_				
378	Friday, 27 December, 2024		EXAMINATION	X RESI	J	
379	Saturday, 28 December, 2024	•				
380	Sunday, 29 December, 2024		WEEKLYOFF			
381	Monday, 30 December, 2024					
382	Tuesday, 31 December, 2024					
383	Wednesday, 1 January, 2025	T	EXAMINATION	& DECI	TTT	
384	Thursday, 2 January, 2025		LAAMIINA LIUN	W NLS		
385	Friday, 3 January, 2025					
386	Saturday, 4 January, 2025					
387	Sunday, 5 January, 2025		WEEKLYOFF			
388	Monday, 6 January, 2025					
389	Tuesday, 7 January, 2025					
390	Wednesday, 8 January, 2025	I	EXAMINATION	Q. DECI	TTT	
391	Thursday, 9 January, 2025	I	VAAMIINATION	C NLS		
392	Friday, 10 January, 2025					
393	Saturday, 11 January, 2025					
394	Sunday, 12 January, 2025		WEEKLYOFF			
395	Monday, 13 January, 2025	_			TT 783	
396	Tuesday, 14 January, 2025		EXAMINATION	XKKSI	J 🖟 🔏 🐪	
397	Wednesday, 15 January, 2025					
		N	OTE: Holidays marked (*) are subjec	t to appearance	of moon.	
			COLOR CODE	·	-	
		Sr. No.	SUBJECT	COLOR	COLOR NAME	1
		1	PATHOLOGY		PINK	╡
		2	MICROBIOLOGY		YELLOW	
		3	PHARMACOLOGY		GREEN	
		4	MEDICINE		BLUE	=
		5			PEACH	-
			OBS & GYNE			
		6	FMT		RED	
		7	COMMUNITY MEDICINE		LIGHT BROWN	4
		8	SURGERY		GREY	

	9	PATHOLOGY / MICROBIOLOGY / PHARMACOLOGY PRACTICALS (GROUP A/B)	TEAL	
	10	CLINICAL POSTING	WHITE	
	11	AETCOM	LIGHT GREEN	